Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone As Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.Martin F. Kaiser,Andrew Hall,Katrina Walker,Amy Sherborne,Ruth M. De Tute,Nicola Newnham,Sadie Roberts,Emma Ingleson,Kristian Bowles,Mamta Garg,Anand Lokare,Christina Messiou,Richard S. Houlston,Graham Jackson,Gordon Cook,Guy Pratt,Roger G. Owen,Mark T. Drayson,Sarah R. Brown,Matthew W. JennerJournal of clinical oncology（2023）引用 7|浏览72暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
